Home/Lisata Therapeutics/John D. Menditto
JD

John D. Menditto

Vice President, Investor Relations and Corporate Communications

Lisata Therapeutics

Therapeutic Areas

Lisata Therapeutics Pipeline

DrugIndicationPhase
certepetide (LSTA1)First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)Phase 2